Villegas Victor M, Gold Aaron S, Berrocal Audina M, Murray Timothy G
Ocular Oncology and Retina, Miami, FL, USA.
Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
Clin Ophthalmol. 2014 May 16;8:973-6. doi: 10.2147/OPTH.S62816. eCollection 2014.
To evaluate the impact of intravitreal bevacizumab combined with laser vascular ablation in the management of advanced Coats' disease presenting with exudative retinal detachment.
This was a retrospective review of 24 children that presented with exudative retinal detachments associated with advanced Coats' disease. Mean patient age was 62 months (range 9-160 months). Presenting signs included retinal detachment in 24 children (100%), vascular telangiectasia in 24 children (100%), and retinal ischemia in 24 children (100%). Twenty of 24 children presented with elevated, vascular leakage in the fovea (83%). Two children presented with sub-retinal fibrosis associated with presumed long-standing retinal detachment without evidence of rhegmatogenous retinal detachment. Ten patients exhibited vascular alterations in the periphery of the second eye without clinical evidence of exudation. All 24 children were treated with a large-spot-size diode laser directly to areas of abnormal telangiectatic vasculature. All 24 children received intravitreal bevacizumab injection.
All 24 children had resolution of exudative retinal detachment, ablation of vascular telangiectasia, and anatomic improvement of the retina. No child exhibited progressive retinal detachment and no eye required enucleation. No cases of neovascular glaucoma were seen. Fellow eyes with peripheral vascular alterations showed no progression to exudative vasculopathy during the observation period. Intravitreal bevacizumab injection was not associated with endophthalmitis or systemically-observed complications.
Repetitive intravitreal bevacizumab combined with laser vascular ablation may be utilized effectively for advanced Coats' disease presenting with exudative retinal detachment.
评估玻璃体内注射贝伐单抗联合激光血管消融术对伴有渗出性视网膜脱离的晚期科茨病的治疗效果。
回顾性分析24例伴有晚期科茨病并渗出性视网膜脱离的患儿。患儿平均年龄62个月(9 - 160个月)。主要体征包括24例患儿均有视网膜脱离(100%)、24例患儿均有血管扩张(100%)、24例患儿均有视网膜缺血(100%)。24例患儿中有20例黄斑区有血管渗漏且隆起(83%)。2例患儿有视网膜下纤维化,推测与长期视网膜脱离有关,无孔源性视网膜脱离证据。10例患者对侧眼周边血管有改变,但无渗出的临床证据。所有24例患儿均使用大光斑二极管激光直接照射异常扩张的血管区域。所有24例患儿均接受玻璃体内注射贝伐单抗治疗。
所有24例患儿渗出性视网膜脱离均消退,血管扩张被消融,视网膜解剖结构改善。无患儿出现进行性视网膜脱离,无需行眼球摘除术。未见新生血管性青光眼病例。观察期间,周边血管有改变的对侧眼未进展为渗出性血管病变。玻璃体内注射贝伐单抗未引起眼内炎或全身性并发症。
反复玻璃体内注射贝伐单抗联合激光血管消融术可有效治疗伴有渗出性视网膜脱离的晚期科茨病。